PDSB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
PDS Biotechnology Corp (PDSB) is not a strong buy for a beginner, long-term investor at this time. The stock shows no significant positive trading signals, weak financial performance, and lacks clear catalysts for growth. The technical indicators and options data do not suggest a compelling entry point, and the company's financials show declining profitability. While there is a potential catalyst in the amended Phase 3 trial, it is speculative and not enough to justify a buy recommendation for a beginner investor.
The MACD is slightly positive and expanding, indicating mild bullish momentum. However, the RSI is neutral at 54.324, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 0.675, with resistance at 0.732 and support at 0.618. Overall, the technical indicators do not suggest a strong buy signal.
The company amended its Phase 3 VERSATILE-003 trial protocol to include progression-free survival as an interim primary endpoint, which could potentially lead to accelerated approval of PDS0101 for HPV16-positive recurrent and/or metastatic head and neck cancer.
The company's financial performance is weak, with a YoY decline in net income (-16.01%) and EPS (-34.48%). Additionally, there are no significant trading trends from hedge funds or insiders, and the options data indicates low trading activity.
In Q3 2025, revenue remained at 0 with no growth. Net income dropped to -$9,009,411 (-16.01% YoY), and EPS fell to -0.19 (-34.48% YoY). Gross margin remained at 0 with no improvement.
No data available for analyst ratings or price target changes.
